Biovitrum Acquires Oncology Project
Stockholm - Biovitrum AB will acquire a promising oncology project from Axelar AB, a company established by leading researchers at the Karolinska Institute, and Karolinska Innovations AB. The project includes the development of molecules that inhibit the IGF-1 receptor, which is involved in the growth of tumour cells in several ways and may lead to future treatment opportunities for various types of cancer. Through the agreement, Biovitrum gets access to a new chemical entity against cancer, which has demonstrated promising results in pre-clinical studies. “The research done by Axelar is highly interesting and cutting edge. The IGF-1 receptor is a very promising target for cancer treatment,” says Terje Kalland, CSO of Biovitrum. The project will be further developed in collaboration between Biovitrum and Prof. Magnus Axelson and Prof. Olle Larsson, the researchers at the Karolinska Institute who spun-off Axelar AB. “We are very pleased to be able to work together with Biovitrum. The collaboration will give us an opportunity to succeed in our research for finding a new way to treat cancer,” stated Prof. Axelson and Prof. Larsson.